Quick answer: Yes — any UK facility manufacturing food, drugs, medical devices, or cosmetics for the U.S. market must register with the FDA and designate a U.S. Agent, the same baseline requirement as any other country. What makes the UK genuinely different: a real Mutual Recognition Agreement exists between the FDA and the UK's MHRA for pharmaceutical GMP inspections, something most exporting countries don't have. Orionex provides FDA registration and U.S. Agent services for UK exporters starting at $300/year.
Why the UK Needs Its Own Guide, Not the EU One
If you're a UK exporter and assumed our EU registration guide applies to you, it's worth correcting that now: it doesn't. Since completing its departure from the European Union, the UK's Medicines and Healthcare products Regulatory Agency (MHRA) operates as a fully independent regulator, no longer part of the EU's regulatory network or the European Medicines Agency. The FDA treats the UK as a separate regulatory relationship from the EU entirely — with its own dedicated agreements, its own inspection arrangements, and its own points of contact.
The U.S.-UK Mutual Recognition Agreement — A Real Advantage for Drug Manufacturers
Here's what makes UK drug exporters different from exporters in almost every other country in this guide series: the U.S.-UK Mutual Recognition Agreement (MRA) Sectoral Annex for Pharmaceutical Good Manufacturing Practices entered into force on January 1, 2021. Under this agreement, the FDA and MHRA can rely on each other's routine surveillance GMP inspections for human drug manufacturing facilities — meaning a UK facility already inspected and found compliant by MHRA may not need a separate, duplicate FDA GMP inspection for that same routine purpose. The agreement was expanded on September 27, 2021 to cover veterinary pharmaceuticals as well.
Why this matters practically: for a UK pharmaceutical manufacturer, this can mean less duplicated inspection burden compared to manufacturers in countries without an equivalent MRA. It doesn't eliminate FDA registration or U.S. Agent requirements, but it changes the inspection relationship in your favor.
What the MRA Doesn't Cover
The MRA's scope has real limits worth knowing rather than assuming:
- Vaccines for human use — excluded (though FDA and UK have discussed revisiting this)
- Plasma-derived pharmaceuticals — excluded
- Advanced Therapy Medicinal Products (ATMPs) — excluded
- Human blood, plasma, tissues, and organs — excluded
- Veterinary immunological products — excluded
- Investigational products (clinical trial material) — excluded
If your product falls into one of these categories, the standard FDA registration and inspection framework applies without the MRA's inspection-sharing benefit.
A New Development for Medical Devices — Framework, Not Yet Operational
On April 7, 2026, the MHRA and FDA announced strengthened regulatory cooperation specifically on medical devices, as part of a wider US-UK trade and partnership framework. The two agencies committed to technical work exploring closer regulatory alignment and potential future mutual recognition mechanisms for devices.
Important to get right: as of mid-2026, this is a framework commitment, not an operational recognition agreement. No specific device recognition routes have been confirmed yet. UK medical device manufacturers should continue following the standard FDA device registration and inspection process — this announcement signals direction of travel, not a shortcut available today.
The Baseline Requirements Still Apply
Regardless of the MRA and the device cooperation framework, UK exporters follow the same core FDA requirements as exporters from any other country:
- FDA Food Facility Registration for food, beverage, and supplement exporters
- Drug Establishment Registration for pharmaceutical manufacturers
- Medical Device Establishment Registration for device manufacturers
- MoCRA Cosmetic Registration for cosmetic manufacturers
- A U.S. Agent for all of the above
U.S. Agent Requirement for UK Facilities
Every UK facility registering with the FDA — regardless of product category, and regardless of MRA coverage — must designate a U.S. Agent physically located in the United States as its official FDA point of contact.
Orionex Regulatory Solutions is a trusted FDA U.S. Agent for UK exporters across food, drug, device, and cosmetic categories, physically based in Casper, Wyoming USA. Learn about our U.S. Agent services →
UK Exporter Compliance Checklist
Register With the FDA in the Correct Category
Food, drug, device, or cosmetic — the requirements differ by product type.
Designate a U.S. Agent
Required for all UK exporters, regardless of MRA coverage.
Check MRA Applicability If You're a Drug Manufacturer
Confirm your product isn't in one of the excluded categories before assuming reduced inspection burden.
Don't Assume Device Mutual Recognition Yet
The April 2026 announcement is directional, not an active shortcut for device inspections.
Renew on Schedule
Food facilities renew biennially — next window: October 1 – December 31, 2026. See our renewal guide.
What Orionex Provides for UK Exporters
The FDA charges no government fee for food facility registration. Orionex's fixed pricing:
- Food Facility Registration + U.S. Agent + Certificate: $300/year
- Drug Establishment Registration + U.S. Agent: $550/year
- Medical Device Establishment Registration + U.S. Agent: $550/year
- MoCRA Cosmetic Registration + U.S. Agent: $650/year
Note: Orionex handles your FDA registration and U.S. Agent designation across all product categories. Questions about how the MRA specifically applies to your drug facility's inspection history are worth raising with a regulatory affairs specialist familiar with both MHRA and FDA frameworks — contact us if you'd like a referral.
Why UK Exporters Choose Orionex
FDA Registration & U.S. Agent for UK Exporters — From $300/Year
Orionex handles FDA registration and U.S. Agent services for UK-based food, drug, device, and cosmetic manufacturers exporting to the United States.